Key points from article :
Seven years ago, AbbVie penned an early-stage deal with Google/Alphabet’s life sciences division Calico.
This deal in 2014 focused on age-related diseases, including neurodegeneration and cancer.
Back in 2018, the pair signed their first extension, putting in an extra $1 billion to keep it going.
Today, another $1 billion goes into the pot, and another extension, bringing the collab from 2022 to 2025.
Calico is responsible for research and early development and will push the projects into phase 2a.
AbbVie will continue its early R&D efforts and has an option to manage late-stage development and the sales side.
Since the collaboration, researchers have produced more than two dozen early-stage programs in oncology and neuroscience.
Its lead immuno-oncology target is currently in phase 1 studies which act at multiple steps in the cancer immunity cycle.
“..could yield both novel insights into the biology of aging and first-in-class targets for age-related diseases," - Calico CEO Arthur Levinson.
